Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study
Purpose. To investigate the efficacy of telbivudine (LdT) in blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) during late pregnancy. Methods. A total of 651 pregnant women aged 18-40 in Nantong Third People’s Hospital and Hospital affiliated to Nantong University with positive...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2019/9046260 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567836843704320 |
|---|---|
| author | Mengzhi Cai Yanli Hao Jianxin Zhong Wei Yao Xia Cao Guifang Gu Gang Qin |
| author_facet | Mengzhi Cai Yanli Hao Jianxin Zhong Wei Yao Xia Cao Guifang Gu Gang Qin |
| author_sort | Mengzhi Cai |
| collection | DOAJ |
| description | Purpose. To investigate the efficacy of telbivudine (LdT) in blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) during late pregnancy. Methods. A total of 651 pregnant women aged 18-40 in Nantong Third People’s Hospital and Hospital affiliated to Nantong University with positive hepatitis B surface antigen (HBsAg) and HBV DNA were enrolled between January 2011 and December 2015. Patients with HBV DNA≥106 copies/mL (n=251) received LdT during late pregnancy according to the patients’ will, while 136 high viral patients with HBV DNA≥106 copies/mL who did not take LdT therapy and 268 low viral patients with HBV DNA<106 copies/mL served as the controls. Results. At 7 months and 1 year postpartum, the basal HBV DNA serum level of treated patients declined significantly (P<0.001), while no obvious decline was observed in the untreated high viraemic controls (P<0.05) and untreated low viraemic controls (P<0.05). Only 1 infant (0.4%) in LdT group was HBsAg positive at 7 months, while 14 (5.2%) were in the untreated low viraemic controls (P<0.001) and 15 (11.0%) were in untreated high viraemic controls (P<0.001). Conclusion. For pregnant women with HBV DNA≥106 copies/mL, the use of LdT during late pregnancy could effectively reduce the MTCT rate of HBV. |
| format | Article |
| id | doaj-art-f30daee7c23b4df88a5e436dda33ded5 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-f30daee7c23b4df88a5e436dda33ded52025-02-03T01:00:26ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972019-01-01201910.1155/2019/90462609046260Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective StudyMengzhi Cai0Yanli Hao1Jianxin Zhong2Wei Yao3Xia Cao4Guifang Gu5Gang Qin6Center for Liver Diseases, Nantong Third People’s Hospital, Nantong University, Nantong 226006, ChinaCenter for Liver Diseases, Nantong Third People’s Hospital, Nantong University, Nantong 226006, ChinaDepartment of Obstetrics and Gynaecology, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Obstetrics and Gynaecology, Affiliated Hospital of Nantong University, Nantong 226001, ChinaDepartment of Obstetrics and Gynaecology, Nantong Third People’s Hospital, Nantong University, Nantong 226006, ChinaDepartment of Obstetrics and Gynaecology, Nantong Third People’s Hospital, Nantong University, Nantong 226006, ChinaCenter for Liver Diseases, Nantong Third People’s Hospital, Nantong University, Nantong 226006, ChinaPurpose. To investigate the efficacy of telbivudine (LdT) in blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) during late pregnancy. Methods. A total of 651 pregnant women aged 18-40 in Nantong Third People’s Hospital and Hospital affiliated to Nantong University with positive hepatitis B surface antigen (HBsAg) and HBV DNA were enrolled between January 2011 and December 2015. Patients with HBV DNA≥106 copies/mL (n=251) received LdT during late pregnancy according to the patients’ will, while 136 high viral patients with HBV DNA≥106 copies/mL who did not take LdT therapy and 268 low viral patients with HBV DNA<106 copies/mL served as the controls. Results. At 7 months and 1 year postpartum, the basal HBV DNA serum level of treated patients declined significantly (P<0.001), while no obvious decline was observed in the untreated high viraemic controls (P<0.05) and untreated low viraemic controls (P<0.05). Only 1 infant (0.4%) in LdT group was HBsAg positive at 7 months, while 14 (5.2%) were in the untreated low viraemic controls (P<0.001) and 15 (11.0%) were in untreated high viraemic controls (P<0.001). Conclusion. For pregnant women with HBV DNA≥106 copies/mL, the use of LdT during late pregnancy could effectively reduce the MTCT rate of HBV.http://dx.doi.org/10.1155/2019/9046260 |
| spellingShingle | Mengzhi Cai Yanli Hao Jianxin Zhong Wei Yao Xia Cao Guifang Gu Gang Qin Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study Canadian Journal of Gastroenterology and Hepatology |
| title | Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study |
| title_full | Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study |
| title_fullStr | Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study |
| title_full_unstemmed | Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study |
| title_short | Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study |
| title_sort | telbivudine treatment during late pregnancy prevents mother to child transmission of hepatitis b virus a retrospective study |
| url | http://dx.doi.org/10.1155/2019/9046260 |
| work_keys_str_mv | AT mengzhicai telbivudinetreatmentduringlatepregnancypreventsmothertochildtransmissionofhepatitisbvirusaretrospectivestudy AT yanlihao telbivudinetreatmentduringlatepregnancypreventsmothertochildtransmissionofhepatitisbvirusaretrospectivestudy AT jianxinzhong telbivudinetreatmentduringlatepregnancypreventsmothertochildtransmissionofhepatitisbvirusaretrospectivestudy AT weiyao telbivudinetreatmentduringlatepregnancypreventsmothertochildtransmissionofhepatitisbvirusaretrospectivestudy AT xiacao telbivudinetreatmentduringlatepregnancypreventsmothertochildtransmissionofhepatitisbvirusaretrospectivestudy AT guifanggu telbivudinetreatmentduringlatepregnancypreventsmothertochildtransmissionofhepatitisbvirusaretrospectivestudy AT gangqin telbivudinetreatmentduringlatepregnancypreventsmothertochildtransmissionofhepatitisbvirusaretrospectivestudy |